DR. TARA MICHELLE GRAFF DO NPI 1356584080

NPI Details

DR. Tara Michelle Graff, DO is a medical oncology internal medicine in Clive, IA with 17 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. DR. Tara Michelle Graff, DO NPI is 1356584080. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

Education
Medical School: LAKE ERIE COLLEGE OF OSTEOPATHIC MEDICINE, ERIE
Graduation Year:2009

The provider's business location address is:

12495 UNIVERSITY AVE STE 200
CLIVE, IA
ZIP 50325-290
Phone: (515) 282-2921
Fax: (515) 643-8819

The NPI 1356584080 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, iron sucrose, 1 mg (HCPCS:J1756)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, rituximab-abbs, biosimilar, (truxima), 10 mg (HCPCS:Q5115)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Phosphate level (HCPCS:84100)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Uric acid level, blood (HCPCS:84550)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Folic acid level, serum (HCPCS:82746)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Magnesium level (HCPCS:83735)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Red blood count automated, with additional calculations (HCPCS:85046)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Unclassified drugs (HCPCS:J3490)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or (HCPCS:G2212)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus (HCPCS:87426)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Hospital discharge day management, more than 30 minutes (HCPCS:99239)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)

The enumeration date for this NPI number is 4/10/2009 and was last updated on 11/18/2025.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: